GRP and central nervous system neoplasm: This paradigm elucidates subtype‐specific vulnerabilities (e.g., ECM remodeling, immune evasion) and resistance mechanisms (e.g., metabolic rewiring), while synergizing Bn/BnR pathway insights, niche modeling, and probe‐based validation to advance personalized CNS tumor management.